| Home | Search | Study Topics | Glossary |
|
|
|
 |
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||||||||||||||||||||||||||||||
| Sponsors and Collaborators: |
National Institute on Drug Abuse (NIDA) University of Texas |
| Information provided by: | National Institute on Drug Abuse (NIDA) |
| ClinicalTrials.gov Identifier: | NCT00000307 |
Purpose
The purpose of this study is to evaluate naltrexone as an adjunct in alcoholic cocaine dependent patients; concurrent relapse prevention theory.
| Condition | Intervention | Phase |
|
Alcohol-Related Disorders Cocaine-Related Disorders |
Drug: Naltrexone |
Phase II |
| Drug Information available for: | Naltrexone 8-Azabicyclo(3.2.1)octane-2-carboxylic acid, 3-(benzoyloxy)-8-methyl-, methyl ester, (1R-(exo,exo))- Cocaine hydrochloride Naltrexone hydrochloride |
| Study Type: | Interventional |
| Study Design: | Treatment |
| Official Title: | Naltrexone as an Adjunct in Alcoholic Cocaine Dependent Patients |
| Estimated Enrollment: | 0 |
| Study Start Date: | April 2003 |
| Study Completion Date: | April 2007 |
| Primary Completion Date: | April 2007 (Final data collection date for primary outcome measure) |
Eligibility
| Ages Eligible for Study: | 18 Years to 50 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Please contact site for information.
Contacts and Locations| United States, Texas | |||||
| University of Texas Health Science Center | |||||
| Houston, Texas, United States, 77225 | |||||
| National Institute on Drug Abuse (NIDA) |
| University of Texas |
| Principal Investigator: | John Grabowski, Ph.D. | University of Texas |
More Information
| Responsible Party: | University of Texas Medical School at Houston ( Joy Schmitz, Ph.D. ) |
| Study ID Numbers: | NIDA-09262-4, P50-09262-4 |
| First Received: | September 20, 1999 |
| Last Updated: | August 11, 2008 |
| ClinicalTrials.gov Identifier: | NCT00000307 |
| Health Authority: | United States: Federal Government |
|
|
|
|
|
